Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is a life sciences company that is developing a portfolio of gene therapy candidates for neuromuscular and cardiac diseases. They are currently focused on five programs, including SGT-003 for the treatment of Duchenne muscular dystrophy, which is showing promising early results in clinical trials. With a differentiated approach to gene therapy and upcoming clinical milestones, we believe Solid Biosciences has the potential to become a top player in the field of genetic medicine and generate significant revenue in the future.

Bears say

Solid Biosciences is currently facing financial struggles, reporting no revenue in 1Q26 and projecting a net loss of $1.72 per share for 2026. While they have a strong cash balance of $381M, this may not be enough to sustain their operations until 1H28 due to ongoing research and development efforts. Additionally, the company's gene therapy treatments for Duchenne muscular dystrophy and other diseases may face significant challenges in the regulatory process, potentially delaying potential market entry and hindering the company's financial performance.

Solid Biosciences (SLDB) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Solid Biosciences (SLDB) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.